Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Resverlogix Corp T.RVX

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  RVXCF

Resverlogix Corp is a clinical stage cardiovascular company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease.
Price: $2.08 | Change: +$0.29 | %Change: +16.20%
Volume: 114,130 | Day High/Low: 2.11/1.80 | 52 Week High/Low: 3.13/0.405
View modes: 
5 stars

RE:Zack Report

Yeah, you're probably right. A successful Phase 3 wouldn't attract any attention from the media, analysts, big pharma, or attract any additional retail investors. And a potential Nasdaq listing along...read more
0 stars

Zack Report

Wow! Looking at the projections...we go into the end of 2020 with negative earnings of $20MM. Hard to visualize a double digit stock price in the next few years...even with a successful Phase III.  rate and reply
0 stars

THE PINKS

Resverlogix Corp.   Ordinary SharesInternational Reporting OTC Pink Current Information  1.210.0126 (1.05%) Real-Time Best Bid...read more
5 stars

RE:RE:RE:RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

My mistake.....first mention of MACE was either at the August 29 2013 conference call/webcast or the Sept 3 2013 news release. Still within my 2 year window!  rate and reply
5 stars

RE:RE:RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

Toniv, Your statement "From your comments it does seem that the impact of rvx-208 may be modest at best OR like all of the complexities of biological life...the impact is very selective e.g. DM, CVD...read more
0 stars

RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

Superb rambling Toinv. Please keep them coming!  rate and reply
0 stars

RE:RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

BDAZ, thanks for straightening me out and giving us the facts and science. I find it remarkable how you can@weave@through all of the research and bring objectivity and perspective. I@thought I had...read more
5 stars

RE:RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

BDAZ, thanks for straightening me out and giving us the facts and science. I find it remarkable how you can weave through all of the research and bring objectivity and perspective. I thought I had...read more
5 stars

RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

Toniv wrote: "We know that in both the ASSURE and SUSTAIN trials that rvx-208 increased ApoA-l (good, functional HDL cholestoral - the kind that results in reverse cholesterol; transport hence reduced...read more
3 stars

RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

toinv...you summarized it pretty good....and well thought out. We're up a bit  thus far today.  I took trussell's lead so I added some yesterday.    G1945V  rate and reply
5 stars

RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

toinv...you summarized it pretty good....and well thought out. We're up a bit  thus far today.  I took trussell's lead so I added some yesterday.    G1945V  rate and reply
3 stars

Zacks /SCR Report Update on RVX

http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2015/RVX-With-Financing-in-Place-Phase-3-BETonMACE-Set-to-Commence-Fall-2015/default.aspx  rate and reply
5 stars

RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

Hi Jkj. Thank you for the post!!! I find the 4th paragraph very interesting re RVX. What it says is that each of the PCSK9 reducing drugs significantly lower LDL. Then, however, it says that it is...read more
5 stars

RE:RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

A very serious problem, especially for those in the states. Many of my meds have doubled in price in the last year. A month of Crestor is $395. When I travel to CleveClinic, I take a ride down the...read more
0 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:DM- expirations of options

four, re a) i share your perspective on RVX's CEO, which why i unlike others it seems, pretty much discount pretty much everything he spouts re. b) don't know if you noticed but BoM is morphing into...read more
0 stars

RE:INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

jk, this is what BIOSPACE.com reported on August 11, 2015, on this subject on the high cost of PCSK-9 inhibitors: "The authors of the JAMA letter wrote, “The best approach will be to promote use of...read more
5 stars

INTERESTING ARTICLE RE CVS AND DRUG PRICING FYI

CVS isn't stopping with PCSK9 discount demands. It wants concessions from ACC/AHA, too CVS Health has no intention of shelling out more than it has to on the new PCSK9 drugs. It's been saying so for...read more
4 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:DM- expirations of options

Hi Poc, regarding your reply to my post; a) I was perhaps being a little facetious but I would still say at this point the CEO of RVX is less important wrt an investment as opposed to the CEO in a...read more
0 stars

FYI RE JAMES BIOTECH

http://www.james-biotechs.com/investment-portfolio/rvx  rate and reply
5 stars

RVX in the next 7 weeks

Here are the events leading up to the Resverlogix Annual General Meeting on September 30th.   August 29 - September 2: European Society of Cardiology (ESC) Congress 2015, London, England. Norman...read more